{"id":"NCT00530348","sponsor":"Genzyme, a Sanofi Company","briefTitle":"Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","officialTitle":"A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients With Relapsing-Remitting Multiple Sclerosis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-08","primaryCompletion":"2011-04","completion":"2011-04","firstPosted":"2007-09-17","resultsPosted":"2014-11-24","lastUpdate":"2014-11-24"},"enrollment":581,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis, Relapsing-Remitting"],"interventions":[{"type":"BIOLOGICAL","name":"Alemtuzumab","otherNames":["Lemtrada"]},{"type":"BIOLOGICAL","name":"Interferon beta-1a","otherNames":["Rebif®"]}],"arms":[{"label":"Alemtuzumab","type":"EXPERIMENTAL"},{"label":"Interferon Beta-1a","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study was to establish the efficacy and safety of alemtuzumab (Lemtrada™) as a treatment for relapsing-remitting multiple sclerosis (MS), in comparison with subcutaneous (SC) interferon beta-1a (Rebif®). The study had enrolled participants who had not previously received MS disease-modifying therapies. Participants had monthly laboratory tests and comprehensive testing every 3 months.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Accumulation of Disability (SAD)","timeFrame":"Up to 2 years","effectByArm":[{"arm":"Interferon Beta-1a","deltaMin":11.12,"sd":null},{"arm":"Alemtuzumab","deltaMin":8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.2173"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":9},"locations":{"siteCount":101,"countries":["United States","Argentina","Australia","Brazil","Canada","Croatia","Czechia","France","Germany","Mexico","Poland","Russia","Serbia","Sweden","Ukraine","United Kingdom"]},"refs":{"pmids":["23122652","39935588","37745914","37272540","36619856","34882037","34378446","34035833","33414927","32710396","31762387","31675266","31654272","30144037","28835401","27590291"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":27,"n":187},"commonTop":["Headache","Rash","Pyrexia","Multiple sclerosis relapse","Nasopharyngitis"]}}